News

Could mavacamten be a key player in implementing pharmacogenetics in cardiovascular prescribing?

We are pleased to share our publication (McGurk et al. 2024) in Circulation on the pharmacogenetic influences over mavacamten pharmacokinetics.

Mavacamten is a first-in-class, orally administered, cardiac-specific, small-molecule allosteric modulator of β-cardiac myosin. Mavacamten reversibly inhibits the binding of β-cardiac myosin to actin to reduce hypercontractility in an exposure-dependent manner.

DNA variants can alter the therapeutic and adverse effects of drugs at recommended dosages. Variants in genes encoding cytochrome P450 enzymes, expressed in the liver and small intestine, are associated with variable drug metabolism. Individuals can be categorized into 5 metabolizer phenotypes: poor, intermediate, extensive (sometimes described as normal), rapid, and ultrarapid. CYP2C19 is the dominant metabolizer of mavacamten and poor metabolizers, attributable to diplotypes of 2 CYP2C19 alleles [the CYP2C19*2 (p.Pro227Pro;c.681G>A; rs4244285) and CYP2C19*3 (p.Trp212Ter;c.636G>A; rs4986893) alleles], are at increased risk of systolic dysfunction from mavacamten treatment at the recommended dose. Individual metabolizer status is further complicated by additional variation across other common alleles within this gene, other CYP450 genes, and other relevant pathways.

The prevalence of poor metabolizers (PMs) is common and varies by population (below). The half-life is extended to 23 days in PMs from 9 days in normal metabolisers (NMs). In NMs, it takes ~4 weeks (five half-lives) to eliminate mavacamten from the body after treatment discontinuation.

The EMA and UK Medicines and Healthcare Products Regulatory Agency recommend genotyping for CYP2C19 to determine the appropriate dose. If treatment is initiated without metabolizer status determination, dosage should follow as described for poor metabolizers (starting at 2.5 mg once daily and a maximum dose of 5 mg once daily). The recommended starting dose for all other metabolizers is 5 mg once daily and a maximum dose of 15 mg once daily. Dose modifications are provided for concomitant medicinal products, including CYP2C19 and CYP3A4 inhibitors and inducers. The EMA and Australian Therapeutic Goods Administration suggest a simulated 5 mg dose in a poor metabolizer is similar to the maximum dose (15 mg) in a normal metabolizer.

It remains unclear how the EMA genotyping recommendation will be implemented across diverse European health care systems. Genetic testing for variants in sarcomere-encoding genes is used for individuals with HCM to establish the molecular etiology; pharmacogenetic analysis could be incorporated for individuals who have not already undergone testing and allow for the EMA recommended dosage stratification.

The NICE guidelines note uncertainty surrounding the impact of sarcomeric variants on treatment effect (section 3.7): the relationship between treatment response and genotype has not been fully characterised, with the possibility of differences between individuals with and without sarcomere variants and/or with variants in thick vs thin filament genes.

Providing the appropriate mavacamten dosage to each individual with oHCM from treatment initiation should allow for improved quality of life at the lowest risk of adverse events, cost, and burden to health care systems. Prescribers must be aware of the potential for metabolic variability across and within different ancestries and clinical vigilance with close monitoring will be required to avoid adverse events. Successful treatment requires improving symptoms of oHCM in rapid metabolizers and minimizing the risk of drug-induced systolic dysfunction in poor metabolizers. Treatment without genotyping risks reduced ejection fraction in poor metabolizers or increased time to therapeutic dose in normal metabolizers. With limited medications for the management of oHCM, or where there is limited access to septal reduction therapy, effective titration of cardiac myosin inhibitors is vital to the success of treatment. Whereas future clinical trials with improved metabolizer and ancestral representation will aid our understanding in this area, CYP2C19 genotyping may allow for less frequent clinical monitoring and reduced costs.

We also discuss i) only NICE recommends mavacamten as an add-on to standard care and notes long waiting times for echo; ii) Tian et al 2023 which studied 7 PMs; iii) the potential for predose mavacamten plasma concentration measurement (based on 21 individuals of phase 1 trial).

The NHS England National Genomics Education Programme has also released some guidance and an example clinical scenario

This is just one example of how common DNA variants influence cardiovascular treatment. Pharmacogenetic influences are known and reported for drugs during trials, but to date are used clinically only in a few areas. Further implementation in a cardiovascular setting would allow for reduced adverse events, time to therapeutic dose, and titration, of drug interventions.

New £14 million investment targets rare diseases

The UK Rare Disease Research Platform has been established with a £14 million investment over five years by the Medical Research Council (MRC) and the National Institute for Health and Care Research (NIHR). It is made up of a central coordination and administrative hub and eleven specialist nodes based at universities across the UK.

Imperial is leading on the Cardiovascular Rare Disease node with James Ware, Professor of Cardiovascular and Genomic Medicine at the National Heart and Lung Institute, Imperial and MRC Investigator at the MRC London Institute of Medical Sciences. The node leadership team, who will be leading specific projects for the node are Dr Tom Lumbers (UCL), Dr Kate Thomson (Oxford University) and Professor Cathie Sudlow (BHF Data Science Centre, HDRUK).

The aim of the UK Rare Disease Research platform is to bring together expertise from across the UK rare disease research system to foster new and innovative treatments for those directly and indirectly impacted by rare conditions.

Read more about the Rare Disease Research Platform 

Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy

We are delighted to share our recent article (Allouba et al.) on the influence of ethnicity and consanguinity on the genetic architecture of hypertrophic cardiomyopathy.

Accurate interpretation of genetic variants identified in HCM patients represents a major challenge for diagnosis and implementing precision medicine, especially in understudied populations. Therefore, our aim was to define the genetic architecture of HCM in the largest Middle East and North African (MENA) cohort analysed to date by leveraging an ancestry-matched Egyptian case-control cohort recruited to the Aswan Heart Centre. We also compared genetic data between Egyptian and predominantly European patients to identify patterns of genetic variation that are unique to consanguineous populations of MENA ancestry and are likely to be more important contributors to HCM.

We report a markedly higher rate of homozygosity in HCM minor genes MLC- (MYL2, MYL3) and CSRP3 genes compared to major HCM genes (MYBPC3, MYH7), suggesting these variants have low penetrance in heterozygosity, but contribute to recessive disease. Along with the recently reported recessive HCM gene, TRIM63, these genes could be more relevant to consanguineous populations.

We also show that significantly fewer rare variants detected in Egyptian HCM patients could be classified as (likely) pathogenic compared to Europeans due to the underrepresentation of MENA populations in current HCM databases. Integrating methods that leverage Egyptian controls increased the yield of clinically actionable variants (pathogenic, likely pathogenic) from 19% (initial analysis) to 29.6% (cohort-informed analysis)

Collectively, these findings will enhance the utility of clinical genetic testing for understudied populations as well as our understanding of the genetic aetiology of HCM. Analysis of such highly consanguineous cohorts opens new research avenues for the discovery of novel recessive genes in future exome or genome sequencing studies

What is the penetrance of the variants most likely to be identified as secondary findings in cardiomyopathy-associated genes?

We are pleased to share our publication (McGurk et al. 2023) in the American Journal of Human Genetics on the penetrance of  rare variants in cardiomyopathy-associated genes: a cross-sectional approach to estimate penetrance for secondary findings.

The penetrance of cardiomyopathies (CMs) is incomplete and age-related, and expressivity is highly variable. These features present huge challenges for disease management. In particular, the penetrance of individual variants in CM-associated genes is incompletely characterised and poorly understood, especially when identified in asymptomatic individuals without family history.

With the growing availability of whole exome sequencing in wider clinical settings and consumer-initiated elective genomic testing, the importance of estimating the penetrance of individual variants identified as secondary findings (SFs) to guide intervention is ever-increasing. Genes associated with inherited CMs make up one-fifth of the 78 genes recommended by the American College of Medical Genetics and Genomics (ACMG SF v3.1) for reporting SFs during clinical sequencing. Variant-specific estimates of penetrance are required to appropriately inform clinical practice and to fully utilise genetics as a tool to individualise the risk of developing disease in asymptomatic carriers.

We apply a cross-sectional approach, using a method that compares the allele frequency of individual rare variants in large cohorts of cases and reference populations to estimate penetrance. Sequencing data for 10,400 individuals referred for HCM genetic panel sequencing and 2,564 individuals referred for DCM genetic panel sequencing were included in the analysis. To estimate the prevalence of CMs, a literature review and meta-analysis were undertaken, resulting in prevalence estimates for HCM (1:543; 1:1,300 women, 1:360 men) and DCM (1:220; 1:340 women, 1:160 men).

In aggregate, the penetrance by late adulthood of rare, pathogenic variants (23% for HCM, 35% for DCM) and likely pathogenic variants (7% for HCM, 10% for DCM) was substantial for dominant CM. Penetrance was significantly higher for variant subgroups annotated as loss of function or ultra-rare and for males compared to females for variants in HCM-associated genes.

We estimated variant-specific penetrance for 316 recurrent variants most likely to be identified as SFs (51% HCM and 17% DCM cases). 49 variants were observed at least ten times (14% of cases) in HCM-associated genes. Median penetrance was 14.6% (±14.4% SD). We explore estimates of penetrance by age, sex, and ancestry, and simulate the impact of including future cohorts.

This dataset is the first to report the penetrance of individual variants at scale and will inform the management of individuals undergoing genetic screening for SFs. While most variants had low penetrance and the costs and harms of screening are unclear, some carriers of highly penetrant variants may benefit from SFs.

Identification of an increased lifetime risk of major adverse cardiovascular events in UK Biobank participants with scoliosis

We are pleased to share a new article by Valentina Santofimio on research she completed during her masters programme with us.

The abnormal curvature of the spine in scoliosis patients can impact organs within the ribcage including the heart. Most cardiac studies of scoliosis patients to date surround investigations into congenital heart disease. The relationship between scoliosis and non-congenital cardiac manifestations in adults is not well characterised.

Our study focused on investigating the impact of scoliosis on the heart through assessment of cardiac MRI (CMR) traits in the UK Biobank (UKB) adult population cohort. A total of 4,095 (0.8%, 1 in 120) UKB participants were identified to have all-cause scoliosis.

Significant associations were found between scoliosis and older age, female sex, heart failure, valve disease, hypercholesterolemia, diagnosis of hypertension, and decreased enrolment for CMR. We identified altered radial and longitudinal peak diastolic strain rates (PDSR) in participants with scoliosis with CMR available compared to participants without diagnosis of scoliosis. 3D cardiac modelling also showed altered cardiac strain.

A significantly increased lifetime risk of MACE was observed for UKB participants with scoliosis (HR=1.45, P<0.001), mainly driven by heart failure (HR=1.58, P<0.001) and atrial fibrillation (HR=1.54, P<0.001). The probability of MACE doubled in males into older age (from 60 years of age). This may be caused through the altered cardiac diastolic strain rates observed in participants with scoliosis.

The abnormal curvature of the spine can increase mechanical constraint on the heart which may result in diastolic dysfunction and the severity of the spinal deformity has been shown to aggravate ventricular and right atrial pressure.

Scoliosis may be an important modifier of cardiac strain in the adult population. This has clinical implications for the consideration of undertaking scoliosis treatment surgery. However, further research is required to follow up the role of scoliosis in cardiac manifestations in a clinical setting, alongside genetic analyses to assess causality.

Cardiac VariantFX partners with DECIPHER for RELEASE v11.12

Rare and extremely rare variants can be difficult to interpret, and at times genotype-phenotype associations can be hard to determine. DECIPHER is an interactive web-based database of genomic variants and associated phenotypes. It contains data from an international community of more than 270 centers and academic departments that focus on clinical genetics and rare disease genomics. 

The web interface allows for depositing and sharing of genomic variants and phenotypes associated with an individual patient. Centers that deposit a variant can choose to keep data private, share with other members within a pre-defined consortium, or with patient consent can contribute to the open-access data that is available on DECIPHER. 

DECIPHER project sharing has supported collaborations facilitating patient diagnoses, and the use of DECIPHER has contributed to over 2600 published articles since 2004.

DECIPHER was established in 2004 to enable the interpretation and sharing of genotype and phenotype data from rare disease patients. The interpretation of cardiac/cardiovascular disease is complex as these are late-onset, variable penetrance conditions. We have been collaborating with DECIPHER to implement features to enhance the interpretation of cardiac/cardiovascular disease, including the incorporation of additional data and providing a more intuitive experience for cardiac users, specifically when exploring the impact of a particular cardiac variant. In this blog post we describe how cardiac users can utilize the DECIPHER platform, with particular focus on these recent updates.

Flexible search bar

Within the cardiac community, different users (clinicians, diagnostic labs or researchers) may have their variant of interest formatted using a variety of positional identifiers. DECIPHER can now accept variants as search terms in a variety of formats. 

  • Users can identify a gene by HGNC symbol, MANE select transcript or Ensembl identifier
  • Search bar can take the position within the gene as a coding DNA reference, protein reference, or using a “gnomad-style” search based on chromosome and genomic coordinates
  • Reference and alternate alleles can be identified using 1 or 3 letter amino acid codes 
  • Additionally, the input bar allows for space or colon separators, and optional “p.” and “c.” prefix for cDNA and protein reference location 

The result of incorporating these options allows for a wide range of search terms that a user can input to access data about a variant of interest. Most formatting used across the wider cardiac community is now accepted. 

Many of these formats are highlighted under DECIPHER “Search examples” that appear when the search bar is accessed for entry.

Variant summary table

The landing page after entering a search term now leads with a summary that indicates whether the variant has been seen across multiple cohorts and datasets. Quick access to information about the presence of the variant in healthy or disease patients via DECIPHER patients, Deciphering Developmental Disorders (DDD) research variants, ClinVar, gnomAD, and other disease cohorts now including Cardiac VariantFX, can be informative as evidence towards a variant’s pathogenicity.

More information about the variant can be found by clicking on the summary link of a particular cohort.

Cardiac VariantFX Case/Control frequencies

Cardiac VariantFX has collected sequence and variant data from hypertrophic cardiomyopathy patients, dilated cardiomyopathy patients and healthy controls from a total of 7 centres*. Presence or absence of the variant in cardiac disease cohorts and/or confirmed healthy controls can be informative when assessing pathogenicity of a variant that is potentially associated with cardiac disease.

Only variants in genes known to be associated with hypertrophic or dilated cardiomyopathy at the time of processing are available on DECIPHER (ACTC1, BAG3, DES, DSP, FLNC, LMNA, MYBPC3, MYH7, MYL2, MYL3, PLN, RBM20, SCN5A, TNNC1, TNNI3, TNNT2, TPM1, TTN). Note that not all genes are sequenced in each cohort.

Cardiac VariantFX allele counts, allele numbers and calculated frequencies are accessible in DECIPHER’s “Annotation” tab under the “Disease cohorts” and “Cardiac” sub-tabs following a variant search. A tab with cardiac data is only shown when variant data is available for at least one of the cardiac cohorts. The upper panel of Disease Cohorts shows allele statistics as summed by disease status (HCM, DCM, healthy control, gnomAD exome and genome). The following variant counts are from the MYBPC variant ENST00000545968 p.Gln1233Ter.

The lower panel of Disease Cohorts breaks down each Cardiac VariantFX disease status by ethnicity (when available) and provides a histogram for the AC and AN by age for each cohort where age is available.

Gene-disease associations supported by cardiac cohort data

The landing page for each gene or variant search is a Gene-disease associations page (found below the variant summary table). For each gene, there are a number of sources (OMIM, PubMed Gene Reviews, Gene2Phenotype, ClinGen and GenCC) which have investigated conditions that are potentially associated. Associations listed on this page are not always definitive, and some investigations have concluded a lack of association. 

In addition to the sources mentioned above, DECIPHER now also displays associations under a “Case/Control cohort data” heading, which now includes disease associations which have been supported by data included in the cardiac VariantFX cohort data. 

Gene-disease association statistics

Clicking on the association supported by Case/Control cohort data opens a window that contains statistics that have been calculated based on cardiac cohorts** which support the association. Statistics are calculated individually for Truncating variants, Non-truncating variants, and All variants combined. 

This window also contains a shortened text version of the mechanism narrative found in G2P. The full text version of the mechanism narrative can be found via the G2P VEP plugin. 

Descriptions of each statistic can be found by clicking on the (“?”) found next to VariantFX gene-disease metrics. The current release contains statistics based on a subset of Cardiac VariantFX data which is also available at the Atlas of Cardiac Genetic Variation [https://www.cardiodb.org/acgv/]. Future releases will include updated statistics based on the full set of Cardiac VariantFX data, and also include an additional penetrance statistic.

PM1 regions browser

A variant located in a mutational hotspot or well-established functional domain is considered moderate evidence of pathogenicity (PM1, Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology ).

Disease associated genes have been assessed for PM1 (hypertrophic cardiomyopathy  and dilated cardiomyopathy), and the identified regions are now shown in a track of the DECIPHER protein browser. 

Hot spot region (PM1) found in MYH7 visualised in the DECIPHER protein browser.

* Royal Brompton and Harefield Hospitals in London, UK, Aswan Heart Center in Egypt, National Heart Centre Singapore in Singapore, Laboratory for Molecular Medicine of Partners HealthCare Personalized Medicine in Boston, US, Oxford Regional Genetics Laboratory in the UK, GeneDx in Maryland, US, and Northern Ireland Regional Genetics Laboratory in Belfast, UK

** Excess in Disease, Aetiological Fraction, and Odds Ratio

References

Walsh , et al. Genet Med. 2017 Feb;19(2):192-203. doi: 10.1038/gim.2016.90. Epub 2016 Aug 17. PMID: 27532257; PMCID: PMC5116235.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5. PMID: 25741868; PMCID: PMC4544753.

Walsh R, Mazzarotto F, Whiffin N, Buchan R, Midwinter W, Wilk A, Li N, Felkin L, Ingold N, Govind R, Ahmad M, Mazaika E, Allouba M, Zhang X, de Marvao A, Day SM, Ashley E, Colan SD, Michels M, Pereira AC, Jacoby D, Ho CY, Thomson KL, Watkins H, Barton PJR, Olivotto I, Cook SA, Ware JS. Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. Genome Med. 2019 Jan 29;11(1):5. doi: 10.1186/s13073-019-0616-z. PMID: 30696458; PMCID: PMC6350371.

Morales A, Kinnamon DD, Jordan E, Platt J, Vatta M, Dorschner MO, Starkey CA, Mead JO, Ai T, Burke W, Gastier-Foster J, Jarvik GP, Rehm HL, Nickerson DA, Hershberger RE; DCM Precision Medicine study of the DCM Consortium; Variant Interpretation for Dilated Cardiomyopathy: Refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study. Circ Genom Precis Med. 2020 Apr;13(2):e002480. doi: 10.1161/CIRCGEN.119.002480. Epub 2020 Mar 11. PMID: 32160020; PMCID: PMC8070981.

Kelly MA, Caleshu C, Morales A, Buchan J, Wolf Z, Harrison SM, Cook S, Dillon MW, Garcia J, Haverfield E, Jongbloed JDH, Macaya D, Manrai A, Orland K, Richard G, Spoonamore K, Thomas M, Thomson K, Vincent LM, Walsh R, Watkins H, Whiffin N, Ingles J, van Tintelen JP, Semsarian C, Ware JS, Hershberger R, Funke B. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel. Genet Med. 2018 Mar;20(3):351-359. doi: 10.1038/gim.2017.218. Epub 2018 Jan 4. PMID: 29300372; PMCID: PMC5876064.

Genetic Architecture of Acute Myocarditis and the Overlap with Inherited Cardiomyopathy

Dr Amrit Lota
@AmritLota

We are pleased to share our latest publication in Circulation on the genetic architecture of acute myocarditis and the overlap with inherited cardiomyopathy.  

Myocarditis refers to inflammation of the heart muscle. It is traditionally considered to be a random event, which may be triggered by various infections, autoimmune conditions or toxic insults. Whilst most patients show spontaneous recovery, a small but important subset can suffer with long-term adverse cardiac events, including the need for heart transplantation or cardiac device implantation (1).

The purpose of this study was to answer a key question – is there an underlying genetic susceptibility that may explain the wide heterogeneity in clinical outcomes seen with acute myocarditis.

To address this, we compared 3 main cohorts:

– Cohort 1:  230 patients recruited consecutively in London (UK) presenting with acute myocarditis confirmed on cardiovascular magnetic resonance (CMR) or myocardial biopsy (2).

– Cohort 2:  1053 community based healthy volunteers in London with no history of cardiovascular disease and a normal CMR scan.

– Cohort 3:  106 patients presenting with acute myocarditis confirmed on myocardial biopsy in Maastricht (Netherlands).

All participants underwent targeted DNA sequencing for well-characterized cardiomyopathy-associated genes with comparison to healthy controls sequenced on the same platform. The primary outcome was all-cause mortality.

Overall, we found that 8% of patients presenting with acute myocarditis (27 out of 336 cases) carried likely pathogenic variants in ACM or DCM associated genes compared to <1% in healthy volunteers (p<0.0001).

This finding was dominated by truncating variants in Titin (TTN) in 7% of patients, all with left ventricular ejection fraction <50%, compared with 1% in controls (odds ratio, 3.6; P=0.0116). ACM-associated genes were found in 3% of cases versus 0.4% of controls (odds ratio, 8.2; P=0.001). This was driven predominantly by truncating variants in desmoplakin (DSP) in patients presenting with chest pain and preserved LV ejection fraction.

Over a median follow-up of 5.0 years (IQR, 3.9–7.8 years), there was a trend toward greater all-cause mortality in genotype-positive patients compared with genotype-negative patients (5-year mortality risk 11.1% vs 3.3%; P=0.08 after adjusting for age and sex).

We obtained national hospital admission data from NHS Digital (3) and found there were 2353 admissions due to acute myocarditis over the 2-year study period (69% men; median age, 40 years; IQR, 27–55 years). Case ascertainment was calculated at 66%, and the London cohort was confirmed to be representative of national myocarditis admissions. Interestingly, we also found that men were significantly younger than women on admission to hospital (median age 35 years vs 52 years; P<0.001).

In conclusion, in this population-based study ~1 in 13 patients presenting with acute myocarditis were found to have an underlying variant in a gene robustly linked to DCM or ACM that would be reported as likely pathogenic in a patient with cardiomyopathy, compared with <1% in healthy controls. The presence of these variants affected clinical outcomes, particularly with DCM variants being associated with a trend towards greater all-cause mortality.

This study provides novel insights into why a small but important subset of patients with myocarditis experience major adverse events, whilst the majority usually recover spontaneously. It supports the concept that genotype-positive individuals may remain phenotypically silent until the occurrence of an environmental trigger.

This study suggests that genetic counselling and testing should be considered in patients with acute myocarditis, particularly in those with greater LV dysfunction, arrhythmia, or family history of cardiomyopathy. This may inform risk stratification and clinical management, including the need for ongoing surveillance and family screening, when cardiomyopathy-associated genetic variants are present.

A team of researchers with expertise across various disciplines was needed to harness the latest advances in precision phenotyping and genotyping whilst also leveraging national epidemiological datasets to deliver this study. Further work is underway to replicate these findings in a larger multi-centre setting and to provide greater mechanistic insights into genetic predisposition and disease progression in inflammatory cardiomyopathy using a systems biology approach.  

The study was published under open access in Circulation on 26th Sept 2022:

Genetic Architecture of Acute Myocarditis and the Overlap with Inherited Cardiomyopathy | Circulation (ahajournals.org)

The study was also selected for coverage on the American Heart Association News:

Genetics may explain rare heart inflammation in some young people | American Heart Association

Read the news story at the MRC London Institute of Medical Sciences

Genetics may explain rare heart inflammation in young people and athletes | MRC LMS

References:

  1. Grun S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert EM, Hill S, Ong P, Klingel K, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. Journal of the American College of Cardiology. 2012;59:1604-1615
  2. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European heart journal. 2013;34:2636-2648, 2648a-2648d.
  3. https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics

Should we return secondary findings in cardiomyopathy-associated genes?

We are pleased to share our Letter to the Editor published in Genetics in Medicine (McGurk et al. 2022) in response to the latest American College of Medical Genetics & Genomics (ACMG) recommendations on the reporting of secondary findings from clinical sequencing data (ACMG SF) (Miller et al., 2021 a, b).

The increasing availability of genome sequencing in clinical practice provides opportunities for improvements in health.  One specific opportunity is through the early detection of health risks that might allow for preventative intervention. Since 2015 the ACMG has recommended that whenever clinical genome sequencing is undertaken, a defined set of genes should be actively interrogated for DNA variants that might herald a preventable clinical risk, such as a strong inherited predisposition to a specific cancer.

This is a recommendation for a genetic screening programme.  Before implementing screening, it is necessary to understand the benefits and harms of the screening test, and the benefits and harms of any downstream interventions triggered by a positive test.  It is also important to understand the costs of the programme, and who will bear these costs.

Genes associated with inherited cardiac conditions, including cardiomyopathies (heart muscle disease), make up about half of the latest ACMG SF gene list. These conditions can lead to sudden cardiac death, and sadly a fatal heart rhythm problem is sometimes the first manifestation of disease. Identifying people with these conditions early, before they even develop symptoms, is the only way of preventing such deaths.  This is the motivation for screening when genetic data become available through testing for an unrelated condition.

However, not everybody who carries a “disease-causing” variant in a cardiomyopathy gene will develop disease.  We call this incomplete penetrance.  And at present there is huge uncertainty around this – when someone in the population is found to have a “disease-causing” variant, we don’t really know what risk they have of developing cardiomyopathy, and/or of having a dangerous heart rhythm.

We have no doubt that some people will benefit from screening, but others will also be harmed, e.g. through psychological harms, a loss of time or money due to burdensome surveillance, and potentially genetic discrimination.  We do not believe that we have sufficient understanding of the relative benefits and harms to recommend that this should be carried out as standard-of-care.

Patients should be advised of this uncertainty. If a patient chooses to be informed of secondary findings this should ideally be done in the context of research to understand the benefits and harms.

We were particularly motivated to address this following recent update to the list of genes recommended for screening. The ACMG have added TTN (titin) and FLNC (filamin C) to the list of cardiomyopathy genes to evaluate.  We have been studying Titin for some years, and we think that the inclusion of this gene presents huge challenges.  Variants that we would call “likely pathogenic” if found in someone with cardiomyopathy are actually found in about 1 in 200 people in the general population.  The vast majority never develop disease. Is there a net benefit in looking for these variants?  We used data from the UK biobank  to estimate what the benefits of screening might be.

 Secondary findings in FLNC

The authors of the new recommendations say that FLNC variants are highly penetrant, conferring a high risk of cardiomyopathy and arrhythmia.  We agree that people with cardiomyopathy due to variants in FLNC are more likely have rhythm problems than people with some other forms of cardiomyopathy.  However, it has not been shown that these variants are highly penetrant when found in people in the general population.

In this analysis we studied participants in the UK Biobank (UKBB) and found 50 individuals with rare heterozygous FLNC-truncating variants (a similar prevalence to that seen in consortium populations) that would meet criteria for a P/LP annotation and might be returned as secondary findings. None of these individuals were apparently diagnosed with cardiomyopathy.  The benefits of screening for these variants are unclear.

Secondary findings in TTN

0.44% of UKBB participants carried rare (heterozygous) TTN-truncating variants, TTNtv. 1.4% of these were known to have cardiomyopathy when they signed up for the biobank study.  These are therefore not strictly secondary findings.

A further 2.4% (1 in 40) showed evidence of a previously unrecognised cardiomyopathy on a one-off cardiac imaging assessment (derived from the proportion of heterozygous who met criteria for DCM during the UKBB cardiac MRI – CMR).  This gives us an estimate of the number of people we would diagnose with cardiomyopathy if we offered people with SFs in TTN a one-off assessment.

Further individuals developed cardiomyopathy over time.  To detect these would require ongoing surveillance, likely with CMR repeated at intervals.  We estimate that this would detect a further ~3 incident cases per 1,000 person-years of ongoing surveillance in the population of people found to have TTN variants as secondary findings (200 people under surveillance for 5 years each = 1000 person-years).

Modelling adverse outcomes

So far, we have looked at how many people will develop cardiomyopathy.  What we are really interested in is how many people will run into problems that might be preventable by early detection and intervention, particular sudden death.

Based on previous estimates that about 1 in 25 people with established dilated cardiomyopathy might die suddenly over a four-year window, we estimated that to prevent one death we would need to make 25 new diagnoses of cardiomyopathy, which would require us to carry out ~8,000 person-years of surveillance in people found to have TTN variants as secondary findings.

In other words, if we called back 1600 people who had a normal CMR, and repeated the test 5 years later, we might find 25 people who had now developed DCM, and treating these might prevent a single sudden death.

This assumes that the death is entirely preventable with early diagnosis and treatment, which is likely over-optimistic.  Moreover, it ignores the fact that some of these people will not benefit from screening because they have other more immediate health concerns – e.g., they may have had genetic testing because of a cancer, or another rare genetic condition.

An alternative methodology (based on the total observed excess mortality amongst TTN variant carriers, and optimistically assuming that this excess mortality is entirely preventable) suggests that we would need to enrol 100 people into long-term surveillance to prevent 1 death in 10 years.

We therefore believe that while some people will benefit from return of secondary findings, it is premature to recommend this as standard-of-care until we have a better understanding of the benefits and harms of such screening.

Response to McGurk et al.

The authors of the ACMG recommendations responded to our letter (Gollob et al. 2022). They pointed out that the UKBB cohort may underestimate disease prevalence and incidence. We acknowledge the likelihood of survivorship bias in the UKB in our letter but note that the prevalence of DCM is very close to other population estimates, so do not believe that this bias has distorted our estimates importantly.

Furthermore, the UKB cohort likely provides very reasonable estimates for opportunistic screening carried out in adults, e.g., for adult cancer patients, or healthy adults undergoing clinical sequencing because they have a child with a rare genetic condition (for trio analyses).

The authors agreed that more studies are needed on the costs and benefits of reporting SFs and add that they can adapt the future gene lists as new evidence becomes available.

Figure – Visual representation of the potential benefits of opportunistic screening for TTNtv estimated using UK Biobank data. A) Expected findings for a one-off cardiac imaging evaluation of 10,000 individuals with a TTNtv identified as a secondary finding. We estimate that 340 individuals would already be known to have cardiomyopathy, and 240 would be newly identified. CM-related mortality has been estimated as ~4%/4years11,12, so we expect ~10 deaths in this timeframe amongst the newly identified cases, which might plausibly be preventable. This is one estimate of the benefit of opportunity screening, though it is not yet known to what extent early identification would prevent these, particularly given that this population will have other competing risks. Since they are undergoing clinical sequencing for another indication, the morbidity and mortality of that condition would influence the overall value of screening for secondary findings. B) For the 9,420 individuals with no abnormality on initial imaging, we need to consider the potential value of ongoing surveillance, e.g., with serial imaging. For each 10,000 person-years of surveillance we expect 28 new cardiomyopathy diagnoses, with <1 plausibly preventable cardiomyopathy-related death in the next four years (based on mortality rates described above). For comparison, the estimated background mortality in the UK is 93 in 10,000 person-years. The background mortality in a population undergoing clinical sequencing for another indication may be higher. These estimates are based on the UK biobank population, a population of older adults around the typical age of presentation for dilated cardiomyopathy. The yields of one-off and serial evaluation might be expected to be lower in younger individuals. The potential benefit of opportunistic screening for sudden cardiac arrest prevention can also be estimated by directly measuring the incidence of sudden cardiac arrest. Amongst TTNtv heterozygotes in the UK biobank (including individuals already known to have disease, as well as those newly recognised) the incidence is 5/10,132 person-years, i.e., 0.05%, compared with a background SCA incidence of 0.04% in the remainder of the cohort (P>0.05). *Plausibly preventable cardiomyopathy mortality was estimated as 4%/4yr among newly diagnosed cardiomyopathy11,12. **mean death rate in 2019 of registered deaths in 59-69-year-olds in the UK by the Office for National Statistics. The data supporting this figure can be found in the supplementary methods, Table S1, and Figure S1. Of note, these estimates do not account for competing risks.

References

The Heart Hive COVID-19 Study

Researchers from the Cardiovascular Genetics & Genomics Group have published their latest findings in Open Heart journal, using the Heart Hive platform to connect with people with cardiomyopathy.  The paper assesses the effects of the first wave of COVID-19 pandemic on patients with cardiomyopathy using three parallel approaches.

The study has demonstrated that a third of the surveyed patients with cardiomyopathy felt that their physical health deteriorated as a result of the pandemic when assessed shortly after the first wave of the pandemic. This was a significantly higher proportion than those that had reported a suspected COVID-19 infection.

Reported changes in physical health for patients with cardiomyopathy and subjects without heart disease in the Heart Hive COVID-19 study demonstrating that significantly more patients with cardiomyopathy experienced subjective deterioration in physical health. (A) and the reported provision of healthcare for patients with cardiomyopathy during the pandemic (B).

The study further illustrated that many patients had had outpatient clinic appointments rescheduled (29%) or cancelled (16%), and missed clinical investigations (38.9%), procedures (7.6%) or doses of medication (5.3%). Additionally, 40.4% of patients with cardiomyopathy felt that their health needs could not be met by telemedicine.

The findings also indicated that the psychological impact of the pandemic did not differ significantly between patients with cardiomyopathy and subjects without heart disease. Patients with cardiomyopathy did feel that they may be more susceptible to COVID-19 infection and suffer more severe illness if infected.

Approximately 1 in 5 patients with cardiomyopathy had received a recommendation to ‘shield’; a higher proportion of the patients that had received a recommendation to shield reported worsening of their cardiomyopathy symptoms.

We also conducted two other parallel research initiatives alongside the Heart Hive COVID-19 study, which are also published in this article. By studying participants of the Royal Brompton & Harefield Hospital Cardiovascular Research Centre Biobank, we found that patients with DCM and HCM were no more likely to be infected with COVID-19 than the rest of the UK population. However, of the patients with DCM and HCM that were studied, those that had been infected with COVID-19 had more frequently required treatment in hospital during the first wave of the pandemic.

Finally, we used NHS Digital Hospital Episodes Statistics to illustrate that there was a 17.9% year on year reduction in cardiomyopathy-related hospital admissions in 2020, with the lowest hospitalisation rate occurring during the first UK lockdown.

The impact of the COVID-19 pandemic on hospital admissions with a primary diagnosis of dilated cardiomyopathy or hypertrophic cardiomyopathy across NHS England, 2019–2020. Hospital admission data are presented as 28-day moving averages. DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; NHS, National Health Service.
 

To the best of our knowledge, this is the first study to assess both the direct and indirect effects of the COVID-19 pandemic on patients with cardiomyopathy. We hope these findings can be used to adapt clinical services to meet patients’ health needs as the pandemic evolves.

We are very grateful to the Heart Hive participants who contributed to this research initiative and to Cardiomyopathy UK for their ongoing support of this study and the Heart Hive. If you’re taking part in the study, please keep completing your COVID surveys to help us see how COVID-19s effect on people with cardiomyopathy has been changing during the course of the pandemic and with the developments of vaccines and new treatments.

If you haven’t signed up the the Heart Hive and would like to, you can find out more on the Heart Hive home page.

A clinical trial is required to fully assess the effect of taurine administration on dilated cardiomyopathy in humans

The Cardiovascular Genetics and Genomics group is delighted to share the systematic review in Wellcome Open Research (McGurk et al. 2022) entitled “Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review”.

Taurine, 2-aminoethanesulfonic acid, is an essential amino acid found in animal products. Taurine is produced for human consumption as a supplement and ingredient in beverages. Supplementation is a safe, inexpensive, and effective treatment for dilated cardiomyopathy (DCM) in domestic mammals (Pion et al. 1987; Pion et al. 1992; Moise et al. 1991; Keith et al. 2001; Kittleson et al. 1997), however it is currently unlicensed in Europe and the United States for human medical treatment. Recent genome-wide association studies of DCM have identified the locus of the taurine transporter (SLC6A6) (Garnier et al. 2021; Tadros et al. 2021). Additionally, a variant in SLC6A6 has been identified in a consanguineous family with retinal degeneration and mild hypokinetic cardiomyopathy with systolic dysfunction and systolic dilatation of the left ventricle, which corrected with taurine supplementation after 24-months (Ansar et al. 2020). It is unknown whether taurine supplementation can improve human DCM, and furthermore whether improvements are observed when taurine levels are in normal reference ranges.

To assess whether taurine supplementation may be a novel therapeutic option for DCM, we undertook a systematic review. Four electronic databases were searched until 11/03/21. 285 articles were identified, of which eleven met our criteria for inclusion. Taurine supplementation varied across studies; by dose (500 mg to 6g per day), frequency (once to thrice daily), delivery method (tablet, capsule, drink, powder), and duration (2 to 48 weeks). Patient inclusion was all-cause HF patients with ejection fraction (EF) <50% and no study was specific to DCM. While improvements in diastolic and systolic function, exercise capacity, and haemodynamic parameters were described, only EF and stroke volume were measured in enough studies to complete a meta-analysis; the association was not significant with all-cause HF (P<0.05). No significant safety concerns were reported. A formal clinical trial is needed to address whether taurine supplementation is beneficial to the approximately 1/250 individuals with DCM in the population.

How this research came about

The decrease in charity research funding was well publicised in 2020 due to the coronavirus pandemic. I began trying to identify alternative funding sources for future independent research funding. At the time I stayed across the road from a Cats Protection shop. With plenty of time on my hands after work due to UK lockdowns and being new to the field of cardiomyopathy research (without the limits of knowing what is already known), I decided to google whether cats get inherited cardiomyopathies.

Taurine is a regular supplementation for domestic cats presenting with DCM as they lack the ability to create taurine (there are theories around the lack of access of domestic cats to taurine-rich mice). Further research showed that this treatment has been replicated in other domesticated animals. As a geneticist, I did a brief analysis of the taurine metabolic pathway to identify genes where variants may have a potential role in bodily taurine variation, and then assessed the results from a DCM GWAS study we recently published, and I noticed that that one of the hits was in the locus of the taurine transporter (nearest gene LSM3). The lead SNPs are upstream to, and confirmed thyroid eQTLs on GTEx of, the taurine transporter (SLC6A6 or TauT). Without going into detail – the more I dug, the more I found that implicated taurine in DCM and/or altered heart phenotypes.

Why hasn’t a clinical trial for DCM in humans been undertaken?

  1. taurine tablets are cheap and available (no financial gain?)
  2. human plasma measurements may be increased by monocyte activation and thus may be inaccurate.
  3. the mechanism of taurine action is mostly unknown.
  4. DCM GWAS with large sample sizes have only been published very recently.
  5. There is a lack of intersection between veterinary medicine and human sciences (diet-associated DCM in dogs has a group on facebook with 114k members…).

Big thank you to the many members of the group for their support – Rachel Buchan and Katherine Josephs provided much needed sanity checks, James Ware supported the idea from the beginning, Melpi Kasapi helped with the systemmatic review, as well as Paul Barton, Stuart Cook, Brian Halliday, Declan O’Regan, Sean Zheng, Ang Roberts, for discussions.

Written by Dr. Kathryn McGurk

https://doi.org/10.12688/wellcomeopenres.17505.1

References

  • Ansar M, Ranza E, Shetty M, et al.: Taurine treatment of retinal degeneration and cardiomyopathy in a consanguineous family with SLC6A6 taurine transporter deficiency. Hum Mol Genet. 2020; 29(4): 618–623.
  • Garnier S, Harakalova M, Weiss S, et al.: Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. Eur Heart J.; 2021; 42(20): 2000-2011.
  • Keith ME, Ball A, Jeejeebhoy KN, et al.: Conditioned nutritional deficiencies in the cardiomyopathic hamster heart. Can J Cardiol. 2001; 17(4): 449–458.
  • Kittleson MD, Keene B, Pion PD, et al.: Results of the multicenter spaniel trial (MUST): taurine- and carnitine-responsive dilated cardiomyopathy in American cocker spaniels with decreased plasma taurine concentration. J Vet Intern Med. 1997; 11(4): 204–211.
  • McGurk KA, Kasapi M and Ware JS. Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review. Wellcome Open Res 2022, 7:9.
  • Moise NS, Pacioretty LM, Kallfelz FA, et al.: Dietary taurine deficiency and dilated cardiomyopathy in the fox. Am Heart J. 1991; 121(2 Pt 1): 541–547.
  • Pion PD, Kittleson MD, Rogers QR, et al.: Myocardial failure in cats associated with low plasma taurine: A reversible cardiomyopathy. Science. 1987; 237(4816): 764–768.
  • Pion PD, Kittleson MD, Thomas WP, et al.: Response of cats with dilated cardiomyopathy to taurine supplementation. J Am Vet Med Assoc. 1992; 201(2): 275–284.
  • Tadros R, Francis C, Xu X, et al.: Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat Genet. 2021; 53(2): 128-134.